Juliet C. Gray

Southampton, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

Current Perspective: The Role of Liquid Biopsy in Diagnosis and Management of Pediatric Rhabdomyosarcomas (RMS).

Current Perspective: The Role of Liquid Biopsy in Diagnosis and Management of Pediatric Rhabdomyosarcomas (RMS).

Journal: Pediatric hematology and oncology

Published: July 14, 2026

Association Between Dinutuximab Beta Exposure and Post-End-of-Treatment Survival in Neuroblastoma: A Weighted Patient-Level Analysis of Three Clinical Studies.

Association Between Dinutuximab Beta Exposure and Post-End-of-Treatment Survival in Neuroblastoma: A Weighted Patient-Level Analysis of Three Clinical Studies.

Journal: Pediatric blood & cancer

Published: May 10, 2026

Reply to: Signal Worth Trusting-If We Can Reproduce It: Clarifying Overall Response Rate and Progression-Free Survival in BEACON Immuno.

Reply to: Signal Worth Trusting-If We Can Reproduce It: Clarifying Overall Response Rate and Progression-Free Survival in BEACON Immuno.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 30, 2026

The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience.

The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience.

Journal: Pediatric blood & cancer

Published: December 27, 2025

Current treatment strategies for first relapse of high-risk neuroblastoma.

Current treatment strategies for first relapse of high-risk neuroblastoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 16, 2025

Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.

Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 12, 2025

Dinutuximab beta versus historical controls in the treatment of relapsed neuroblastoma: unadjusted and adjusted indirect comparisons.

Dinutuximab beta versus historical controls in the treatment of relapsed neuroblastoma: unadjusted and adjusted indirect comparisons.

Journal: Frontiers in oncology

Published: October 30, 2025

Characterization of patient-derived site-specific in vivo models of pediatric-type diffuse high-grade glioma using magnetic resonance imaging.

Characterization of patient-derived site-specific in vivo models of pediatric-type diffuse high-grade glioma using magnetic resonance imaging.

Journal: Neuro-oncology advances

Published: September 09, 2025

Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancer.

Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 29, 2025

Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison.

Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison.

Journal: Cancers

Published: July 24, 2025

Bone mineral density and vertebral fractures in teenage and young adult patients with acute lymphoblastic leukaemia and lymphoblastic lymphoma: A report from the British OsteoNecrosis Study (BONES).

Bone mineral density and vertebral fractures in teenage and young adult patients with acute lymphoblastic leukaemia and lymphoblastic lymphoma: A report from the British OsteoNecrosis Study (BONES).

Journal: British journal of haematology

Published: June 30, 2025

Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum.

Accelerating Drug Development for Neuroblastoma: Consensus Statement From the Third Neuroblastoma Drug Development Strategy Forum.

Journal: Pediatric blood & cancer

Published: February 26, 2025

Showing 1-12 of 59

Last Updated: 09/26/2026